Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tracy Todd Batchelor, M.D.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA165962 (BATCHELOR, TRACY T) Sep 19, 2013 - Aug 31, 2024
    NIH/NCI
    SPORE: Targeted Therapies for Glioma
    Role: Principal Investigator
  2. R01CA129371 (BATCHELOR, TRACY T) Sep 1, 2007 - Mar 31, 2018
    NIH/NCI
    Angiogenesis-targeting therapy for glioblastoma
    Role: Principal Investigator
  3. K24CA125440 (BATCHELOR, TRACY T) Aug 1, 2007 - Jul 31, 2017
    NIH/NCI
    Clinical and Molecular Studies of Malignant Brain Tumors
    Role: Principal Investigator
  4. R13CA124293 (BATCHELOR, TRACY T) Sep 1, 2006 - Nov 27, 2019
    NIH/NCI
    Annual International Primary CNS Lymphoma Collaborative Group Meeting
    Role: Principal Investigator
  5. R21CA117079 (BATCHELOR, TRACY T) Sep 19, 2005 - Aug 31, 2008
    NIH/NCI
    A Phase 2 study of AZD2171 in Recurrent Glioblastoma
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Karschnia P, Batchelor TT, Jordan JT, Shaw B, Winter SF, Barbiero FJ, Kaulen LD, Thon N, Tonn JC, Huttner AJ, Fulbright RK, Loeffler J, Dietrich J, Baehring JM. Primary dural lymphomas: Clinical presentation, management, and outcome. Cancer. 2020 Mar 16. PMID: 32176324.
    Citations:    
  2. Arrillaga-Romany I, Odia Y, Prabhu VV, Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M, Batchelor TT, Wen PY. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020 Jan 11; 22(1):94-102. PMID: 31702782.
    Citations:    
  3. Li X, Strasser B, Jafari-Khouzani K, Thapa B, Small J, Cahill DP, Dietrich J, Batchelor TT, Andronesi OC. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas. Radiology. 2020 Mar; 294(3):589-597. PMID: 31909698.
    Citations:    
  4. Chang K, Beers AL, Bai HX, Brown JM, Ly KI, Li X, Senders JT, Kavouridis VK, Boaro A, Su C, Bi WL, Rapalino O, Liao W, Shen Q, Zhou H, Xiao B, Wang Y, Zhang PJ, Pinho MC, Wen PY, Batchelor TT, Boxerman JL, Arnaout O, Rosen BR, Gerstner ER, Yang L, Huang RY, Kalpathy-Cramer J. Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol. 2019 11 04; 21(11):1412-1422. PMID: 31190077.
    Citations:    
  5. Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 Jan 01; 26(1):206-212. PMID: 31558474.
    Citations:    
  6. Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608. PMID: 31215634.
    Citations:    
  7. Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019 Oct; 145(1):97-105. PMID: 31456142.
    Citations:    
  8. Nayak L, Batchelor TT. Is it time to revisit R-CHOP for primary CNS lymphoma? Blood. 2019 07 18; 134(3):221-222. PMID: 31320363.
    Citations:    
  9. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 Aug 08; 178(4):835-849.e21. PMID: 31327527.
    Citations:    
  10. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721. PMID: 31197238.
    Citations:    
  11. Batchelor TT. Primary central nervous system lymphoma: A curable disease. Hematol Oncol. 2019 Jun; 37 Suppl 1:15-18. PMID: 31187523.
    Citations:    
  12. Tabrizi S, Yeap BY, Sherman JC, Nachtigall LB, Colvin MK, Dworkin M, Fullerton BC, Daartz J, Royce TJ, Oh KS, Batchelor TT, Curry WT, Loeffler JS, Shih HA. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol. 2019 08; 137:95-101. PMID: 31082632.
    Citations:    
  13. Bale TA, Jordan JT, Rapalino O, Ramamurthy N, Jessop N, DeWitt JC, Nardi V, Alvarez MM, Frosch M, Batchelor TT, Louis DN, Iafrate AJ, Cahill DP, Lennerz JK. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol. 2019 05 06; 21(5):596-605. PMID: 30496526.
    Citations:    Fields:    
  14. Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019 May 06; 21(5):669-677. PMID: 30668823.
    Citations:    Fields:    
  15. Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 2019 04 29; 7(1):66. PMID: 31036078.
    Citations:    
  16. Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 Jul 15; 25(14):4375-4387. PMID: 30975663.
    Citations:    
  17. Winter SF, Loebel F, Loeffler J, Batchelor TT, Martinez-Lage M, Vajkoczy P, Dietrich J. Treatment-Induced Brain Tissue Necrosis: A Clinical Challenge in Neuro-Oncology. Neuro Oncol. 2019 Mar 04. PMID: 30828724.
    Citations:    
  18. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221. PMID: 30808634.
    Citations:    
  19. Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. Oncologist. 2019 05; 24(5):671-679. PMID: 30796152.
    Citations:    
  20. Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019 02 19; 21(3):296-305. PMID: 30418592.
    Citations:    Fields:    
  21. Grommes C, Nayak L, Tun HW, Batchelor TT. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019 02 19; 21(3):306-313. PMID: 30423172.
    Citations:    Fields:    
  22. Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D'Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Frosch MP, Batchelor E, Hoang K, Kuter B, Fortin S, Holdhoff M, Cahill DP, Carter S, Brastianos PK, Batchelor TT. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 2019 02 12; 3(3):375-383. PMID: 30723112.
    Citations:    
  23. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750. PMID: 30715997.
    Citations:    
  24. Arrillaga-Romany I, Curry WT, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT. Performance of a Hospital Pathway for Patients With a New Single Brain Mass. J Oncol Pract. 2019 Mar; 15(3):e211-e218. PMID: 30681891.
    Citations:    Fields:    
  25. Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139. PMID: 30644426.
    Citations:    Fields:    
  26. Seano G, Nia HT, Emblem KE, Datta M, Ren J, Krishnan S, Kloepper J, Pinho MC, Ho WW, Ghosh M, Askoxylakis V, Ferraro GB, Riedemann L, Gerstner ER, Batchelor TT, Wen PY, Lin NU, Grodzinsky AJ, Fukumura D, Huang P, Baish JW, Padera TP, Munn LL, Jain RK. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat Biomed Eng. 2019 03; 3(3):230-245. PMID: 30948807.
    Citations:    
  27. Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313. PMID: 30559168.
    Citations:    Fields:    
  28. Dworkin M, Mehan W, Niemierko A, Kamran SC, Lamba N, Dietrich J, Martinez-Lage M, Oh KS, Batchelor TT, Wen PY, Loeffler JS, Shih HA. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77. PMID: 30488294.
    Citations:    Fields:    
  29. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062. PMID: 30459364.
    Citations:    Fields:    
  30. Löw S, Han CH, Batchelor TT. Primary central nervous system lymphoma. Ther Adv Neurol Disord. 2018; 11:1756286418793562. PMID: 30305848.
    Citations:    
  31. Ly KI, Oakley DH, Pine AB, Frosch MP, Chiou SH, Betensky RA, Pomerantz SR, Hochberg FH, Batchelor TT, Cahill DP, Dietrich J. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. Oncologist. 2019 03; 24(3):402-413. PMID: 30097523.
    Citations:    Fields:    
  32. Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT, Barker FG, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394. PMID: 30082399.
    Citations: 2     Fields:    Translation:HumansAnimals
  33. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. PMID: 29660006.
    Citations: 1     Fields:    
  34. Sinicrope K, Batchelor T. Primary Central Nervous System Lymphoma. Neurol Clin. 2018 08; 36(3):517-532. PMID: 30072069.
    Citations:    Fields:    
  35. Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649. PMID: 29941486.
    Citations:    Fields:    
  36. Dietrich J, Baryawno N, Nayyar N, Valtis YK, Yang B, Ly I, Besnard A, Severe N, Gustafsson KU, Andronesi OC, Batchelor TT, Sahay A, Scadden DT. Bone marrow drives central nervous system regeneration after radiation injury. J Clin Invest. 2018 06 01; 128(6):2651. PMID: 29856368.
    Citations:    Fields:    
  37. Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popovic M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335. PMID: 29674595.
    Citations: 2     Fields:    Translation:HumansCells
  38. Griveau A, Seano G, Shelton SJ, Kupp R, Jahangiri A, Obernier K, Krishnan S, Lindberg OR, Yuen TJ, Tien AC, Sabo JK, Wang N, Chen I, Kloepper J, Larrouquere L, Ghosh M, Tirosh I, Huillard E, Alvarez-Buylla A, Oldham MC, Persson AI, Weiss WA, Batchelor TT, Stemmer-Rachamimov A, Suvà ML, Phillips JJ, Aghi MK, Mehta S, Jain RK, Rowitch DH. A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell. 2018 05 14; 33(5):874-889.e7. PMID: 29681511.
    Citations: 3     Fields:    
  39. Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474. PMID: 29662077.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  40. Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer MC, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol. 2018 04 09; 20(5):642-654. PMID: 29099956.
    Citations:    Fields:    Translation:HumansAnimalsCells
  41. Batchelor T, Wick W. Neuro-Oncology. Semin Neurol. 2018 02; 38(1):3-4. PMID: 29548045.
    Citations:    Fields:    Translation:Humans
  42. Löw S, Batchelor TT. Primary Central Nervous System Lymphoma. Semin Neurol. 2018 02; 38(1):86-94. PMID: 29548055.
    Citations:    Fields:    Translation:Humans
  43. Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018 04; 135(4):639-642. PMID: 29497819.
    Citations: 2     Fields:    
  44. Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 2018 03; 135(3):481-484. PMID: 29372318.
    Citations: 2     Fields:    
  45. Wick A, Kessler T, Elia AEH, Winkler F, Batchelor TT, Platten M, Wick W. Glioblastoma in elderly patients: solid conclusions built on shifting sand? Neuro Oncol. 2018 01 22; 20(2):174-183. PMID: 29016815.
    Citations: 1     Fields:    Translation:Humans
  46. Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J. Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. Neuro Oncol. 2018 01 22; 20(2):289-291. PMID: 29315410.
    Citations:    Fields:    Translation:Humans
  47. Dietrich J, Baryawno N, Nayyar N, Valtis YK, Yang B, Ly I, Besnard A, Severe N, Gustafsson KU, Andronesi OC, Batchelor TT, Sahay A, Scadden DT. Bone marrow drives central nervous system regeneration after radiation injury. J Clin Invest. 2018 01 02; 128(1):281-293. PMID: 29202481.
    Citations: 2     Fields:    
  48. Han CH, Batchelor TT. Primary Central Nervous System Lymphoma. Continuum (Minneap Minn). 2017 12; 23(6, Neuro-oncology):1601-1618. PMID: 29200113.
    Citations:    Fields:    Translation:Humans
  49. Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer. 2017 Nov 15; 123(22):4314-4324. PMID: 28950405.
    Citations:    Fields:    Translation:Humans
  50. Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. NPJ Precis Oncol. 2017; 1(1):33. PMID: 29872714.
    Citations: 1     
  51. Qualls D, Sullivan A, Li S, Brunner AM, Collier K, Hochberg E, Armand P, Batchelor TT, Chen YB, DeFilipp Z. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):884-888. PMID: 28870642.
    Citations: 1     Fields:    Translation:Humans
  52. Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017; 12(8):e0180541. PMID: 28767654.
    Citations: 1     Fields:    Translation:HumansCells
  53. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756. PMID: 28655794.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  54. Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res. 2017 08 01; 77(15):4102-4115. PMID: 28625978.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  55. Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1. PMID: 29202103.
    Citations:    
  56. Han CH, Batchelor TT. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. Chin Clin Oncol. 2017 Jun; 6(3):33. PMID: 28705010.
    Citations: 3     Fields:    Translation:HumansCells
  57. Teng J, da Hora CC, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol. 2017 06 01; 19(6):820-832. PMID: 28062830.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  58. Jordan JT, Miller JJ, Cushing T, Seijo M, Batchelor TT, Arrillaga-Romany IC, Shih HA, Nachtigall LB, Loeffler JS, Dietrich J. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract. 2018 Mar; 5(1):64-68. PMID: 31385986.
    Citations:    
  59. Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 May 12. PMID: 28562358.
    Citations:    
  60. Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 Oct 03; 8(45):79298-79304. PMID: 29108308.
    Citations: 6     Fields: